CD274 and neoplasm: By targeting these two checkpoints simultaneously, this strategy also modulates signals to antigen-presenting cells and diminishes the immunosuppressive effects of Tregs and MDSCs (68).This approach increases tumor sensitivity to PD-L1 blockade and helps overcome immune resistance (69).